 WOBURN, MA, Aug. 31, 2021 GLOBE NEWSWIRE -- SeqLL Inc. SeqLL or the Company NASDAQ:SQL; SQLLW, a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple omics fields, today announced the closing of its previously announced initial public offering of 3,060,000 shares of its common stock and accompanying warrants to purchase up to 3,060,000 shares of common stock. Each share of common stock was sold together with one warrant to purchase one share of common stock with an exercise price of 4.25 per share and an expiration date of five years from the date of issuance at a combined offering price of 4.25, for gross proceeds of approximately 13 million, before deducting underwriting discounts and offering expenses. In addition, SeqLL has granted the underwriters a 45-day option to purchase up to an additional 459,000 shares of common stock andor warrants to purchase 459,000 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount, of which Maxim Group LLC has exercised its option to purchase an additional 459,000 warrants. All of the shares of common stock and warrants were being offered by the Company. 